Does the media refer more to INFU or SRTS?

In the previous week, Sensus Healthcare had 1 more articles in the media than InfuSystem. MarketBeat recorded 2 mentions for Sensus Healthcare and 1 mentions for InfuSystem. Sensus Healthcare's average media sentiment score of 0.94 beat InfuSystem's score of 0.50 indicating that Sensus Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InfuSystem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sensus Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SRTS or INGN?

In the previous week, Inogen had 1 more articles in the media than Sensus Healthcare. MarketBeat recorded 3 mentions for Inogen and 2 mentions for Sensus Healthcare. Inogen's average media sentiment score of 1.32 beat Sensus Healthcare's score of 0.94 indicating that Inogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensus Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inogen 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sensus Healthcare (SRTS) Competitors

$2.71 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$2.73 +0.02 (+0.59%)

As of 06/12/2026 07:25 PM Eastern

Compare

SRTS vs. INFU, STEX, INGN, FOCL, and HYPR

Should you buy Sensus Healthcare stock or one of its competitors? MarketBeat compares Sensus Healthcare with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sensus Healthcare include InfuSystem (INFU), Biosig Technologies (STEX), Inogen (INGN), FocalTherics (FOCL), and Hyperfine (HYPR). These companies are all part of the "medical equipment" industry.

How does Sensus Healthcare compare to InfuSystem?

InfuSystem (NYSE:INFU) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

InfuSystem has a net margin of 1.12% compared to Sensus Healthcare's net margin of -34.50%. InfuSystem's return on equity of 2.78% beat Sensus Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Sensus Healthcare	-34.50%	-15.79%	-14.02%

InfuSystem presently has a consensus price target of $15.00, indicating a potential upside of 64.11%. Sensus Healthcare has a consensus price target of $6.88, indicating a potential upside of 153.69%. Given Sensus Healthcare's higher possible upside, analysts clearly believe Sensus Healthcare is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Sensus Healthcare had 1 more articles in the media than InfuSystem. MarketBeat recorded 2 mentions for Sensus Healthcare and 1 mentions for InfuSystem. Sensus Healthcare's average media sentiment score of 0.94 beat InfuSystem's score of 0.50 indicating that Sensus Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InfuSystem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sensus Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InfuSystem has higher revenue and earnings than Sensus Healthcare. Sensus Healthcare is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$142.40M	1.30	$870K	$0.38	24.05
Sensus Healthcare	$27.48M	1.62	-$7.72M	-$0.47	N/A

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are held by institutional investors. 10.8% of InfuSystem shares are held by insiders. Comparatively, 10.2% of Sensus Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

InfuSystem has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, Sensus Healthcare has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Summary

InfuSystem beats Sensus Healthcare on 11 of the 16 factors compared between the two stocks.

How does Sensus Healthcare compare to Biosig Technologies?

Sensus Healthcare (NASDAQ:SRTS) and Biosig Technologies (NASDAQ:STEX) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Biosig Technologies has a net margin of 0.00% compared to Sensus Healthcare's net margin of -34.50%. Sensus Healthcare's return on equity of -15.79% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensus Healthcare	-34.50%	-15.79%	-14.02%
Biosig Technologies	N/A	-717.92%	-336.75%

Sensus Healthcare has higher revenue and earnings than Biosig Technologies. Sensus Healthcare is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensus Healthcare	$27.48M	1.62	-$7.72M	-$0.47	N/A
Biosig Technologies	$40K	4,418.65	-$462.77M	-$9.71	N/A

25.3% of Sensus Healthcare shares are owned by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are owned by institutional investors. 10.2% of Sensus Healthcare shares are owned by company insiders. Comparatively, 52.7% of Biosig Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Sensus Healthcare had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 2 mentions for Sensus Healthcare and 1 mentions for Biosig Technologies. Biosig Technologies' average media sentiment score of 1.89 beat Sensus Healthcare's score of 0.94 indicating that Biosig Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Sensus Healthcare	Positive
Biosig Technologies	Very Positive

Sensus Healthcare has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Biosig Technologies has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market.

Sensus Healthcare currently has a consensus target price of $6.88, indicating a potential upside of 153.69%. Biosig Technologies has a consensus target price of $8.00, indicating a potential upside of 722.88%. Given Biosig Technologies' higher possible upside, analysts clearly believe Biosig Technologies is more favorable than Sensus Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Sensus Healthcare beats Biosig Technologies on 9 of the 16 factors compared between the two stocks.

How does Sensus Healthcare compare to Inogen?

Sensus Healthcare (NASDAQ:SRTS) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

In the previous week, Inogen had 1 more articles in the media than Sensus Healthcare. MarketBeat recorded 3 mentions for Inogen and 2 mentions for Sensus Healthcare. Inogen's average media sentiment score of 1.32 beat Sensus Healthcare's score of 0.94 indicating that Inogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensus Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inogen	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sensus Healthcare has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Sensus Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensus Healthcare	$27.48M	1.62	-$7.72M	-$0.47	N/A
Inogen	$348.67M	0.50	-$22.75M	-$0.91	N/A

Sensus Healthcare presently has a consensus price target of $6.88, suggesting a potential upside of 153.69%. Inogen has a consensus price target of $14.00, suggesting a potential upside of 118.75%. Given Sensus Healthcare's higher possible upside, analysts clearly believe Sensus Healthcare is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Inogen	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Inogen has a net margin of -7.08% compared to Sensus Healthcare's net margin of -34.50%. Inogen's return on equity of -12.90% beat Sensus Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensus Healthcare	-34.50%	-15.79%	-14.02%
Inogen	-7.08%	-12.90%	-8.27%

25.3% of Sensus Healthcare shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 10.2% of Sensus Healthcare shares are owned by insiders. Comparatively, 2.5% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sensus Healthcare has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Inogen has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

Summary

Inogen beats Sensus Healthcare on 10 of the 17 factors compared between the two stocks.

How does Sensus Healthcare compare to FocalTherics?

Sensus Healthcare (NASDAQ:SRTS) and FocalTherics (NASDAQ:FOCL) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Sensus Healthcare presently has a consensus target price of $6.88, suggesting a potential upside of 153.69%. FocalTherics has a consensus target price of $6.00, suggesting a potential upside of 27.12%. Given Sensus Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Sensus Healthcare is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sensus Healthcare has a net margin of -34.50% compared to FocalTherics' net margin of -41.47%. Sensus Healthcare's return on equity of -15.79% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensus Healthcare	-34.50%	-15.79%	-14.02%
FocalTherics	-41.47%	-137.61%	-40.62%

Sensus Healthcare has higher earnings, but lower revenue than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than Sensus Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensus Healthcare	$27.48M	1.62	-$7.72M	-$0.47	N/A
FocalTherics	$70.53M	2.51	-$29.25M	-$0.81	N/A

25.3% of Sensus Healthcare shares are held by institutional investors. Comparatively, 62.7% of FocalTherics shares are held by institutional investors. 10.2% of Sensus Healthcare shares are held by company insiders. Comparatively, 10.1% of FocalTherics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Sensus Healthcare had 2 more articles in the media than FocalTherics. MarketBeat recorded 2 mentions for Sensus Healthcare and 0 mentions for FocalTherics. Sensus Healthcare's average media sentiment score of 0.94 beat FocalTherics' score of 0.00 indicating that Sensus Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Sensus Healthcare	Positive
FocalTherics	Neutral

Summary

Sensus Healthcare beats FocalTherics on 12 of the 15 factors compared between the two stocks.

How does Sensus Healthcare compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Sensus Healthcare has higher revenue and earnings than Hyperfine. Sensus Healthcare is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	11.84	-$35.57M	-$0.41	N/A
Sensus Healthcare	$27.48M	1.62	-$7.72M	-$0.47	N/A

Sensus Healthcare has a net margin of -34.50% compared to Hyperfine's net margin of -226.88%. Sensus Healthcare's return on equity of -15.79% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
Sensus Healthcare	-34.50%	-15.79%	-14.02%

Hyperfine presently has a consensus price target of $1.78, indicating a potential upside of 31.13%. Sensus Healthcare has a consensus price target of $6.88, indicating a potential upside of 153.69%. Given Sensus Healthcare's stronger consensus rating and higher probable upside, analysts clearly believe Sensus Healthcare is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by company insiders. Comparatively, 10.2% of Sensus Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Hyperfine has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Sensus Healthcare has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

In the previous week, Sensus Healthcare had 1 more articles in the media than Hyperfine. MarketBeat recorded 2 mentions for Sensus Healthcare and 1 mentions for Hyperfine. Hyperfine's average media sentiment score of 1.89 beat Sensus Healthcare's score of 0.94 indicating that Hyperfine is being referred to more favorably in the media.

Company	Overall Sentiment
Hyperfine	Very Positive
Sensus Healthcare	Positive

Summary

Sensus Healthcare beats Hyperfine on 10 of the 16 factors compared between the two stocks.

Get Sensus Healthcare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRTS vs. The Competition

Export

Metric	Sensus Healthcare	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$44.61M	$7.04B	$6.53B	$12.05B
Dividend Yield	N/A	1.21%	2.67%	5.66%
P/E Ratio	-5.77	47.88	23.99	24.42
Price / Sales	1.62	70.95	511.38	110.47
Price / Cash	N/A	25.59	27.48	37.92
Price / Book	0.92	6.84	10.65	6.82
Net Income	-$7.72M	$159.20M	$3.57B	$337.56M
7 Day Performance	0.74%	-0.93%	0.58%	1.17%
1 Month Performance	-24.93%	5.15%	1.54%	3.16%
1 Year Performance	-43.66%	1.23%	25.40%	30.58%

Sensus Healthcare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRTS Sensus Healthcare	3.5039 of 5 stars	$2.71 flat	$6.88 +153.7%	-43.7%	$44.61M	$27.48M	N/A	40	Positive News
INFU InfuSystem	4.0673 of 5 stars	$8.97 -0.4%	$15.00 +67.2%	+47.2%	$181.13M	$142.40M	149.61	410
STEX Biosig Technologies	2.8699 of 5 stars	$0.98 -0.9%	$8.00 +718.8%	N/A	$177.08M	N/A	N/A	50	Positive News
INGN Inogen	3.7351 of 5 stars	$6.39 +5.4%	$14.00 +119.1%	+2.4%	$173.75M	$348.67M	N/A	1,030
FOCL FocalTherics	2.9898 of 5 stars	$4.60 flat	$6.00 +30.4%	N/A	$172.41M	$70.53M	N/A	230	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRTS) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sensus Healthcare (SRTS) Competitors

SRTS vs. INFU, STEX, INGN, FOCL, and HYPR

How does Sensus Healthcare compare to InfuSystem?

Summary

How does Sensus Healthcare compare to Biosig Technologies?

Summary

How does Sensus Healthcare compare to Inogen?

Summary

How does Sensus Healthcare compare to FocalTherics?

Summary

How does Sensus Healthcare compare to Hyperfine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRTS vs. The Competition

Sensus Healthcare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sensus Healthcare (SRTS) Competitors

SRTS vs. INFU, STEX, INGN, FOCL, and HYPR

How does Sensus Healthcare compare to InfuSystem?

Is INFU or SRTS more profitable?

Do analysts recommend INFU or SRTS?

Does the media refer more to INFU or SRTS?

Which has preferable earnings & valuation, INFU or SRTS?

Do institutionals and insiders believe in INFU or SRTS?

Which has more volatility & risk, INFU or SRTS?

Summary

How does Sensus Healthcare compare to Biosig Technologies?

Is SRTS or STEX more profitable?

Which has preferable valuation and earnings, SRTS or STEX?

Do insiders and institutionals believe in SRTS or STEX?

Does the media favor SRTS or STEX?

Which has more risk & volatility, SRTS or STEX?

Do analysts rate SRTS or STEX?

Summary

How does Sensus Healthcare compare to Inogen?

Does the media favor SRTS or INGN?

Which has preferable earnings and valuation, SRTS or INGN?

Do analysts recommend SRTS or INGN?

Is SRTS or INGN more profitable?

Do insiders and institutionals have more ownership in SRTS or INGN?

Which has more volatility and risk, SRTS or INGN?

Summary

How does Sensus Healthcare compare to FocalTherics?

Do analysts rate SRTS or FOCL?

Is SRTS or FOCL more profitable?

Which has better earnings & valuation, SRTS or FOCL?

Do institutionals and insiders believe in SRTS or FOCL?

Does the media prefer SRTS or FOCL?

Summary

How does Sensus Healthcare compare to Hyperfine?

Which has better earnings and valuation, HYPR or SRTS?

Is HYPR or SRTS more profitable?

Do analysts prefer HYPR or SRTS?

Do insiders and institutionals believe in HYPR or SRTS?

Which has more volatility & risk, HYPR or SRTS?

Does the media refer more to HYPR or SRTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRTS vs. The Competition

Sensus Healthcare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools